$SPRO
Spero Therapeutics Inc

2019 Q2 Form 10-Q Financial Statement

#000156459019030746 Filed on August 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2
Revenue $2.156M $463.0K
YoY Change 365.66% 85.94%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.780M $3.060M
YoY Change 23.53% 3.38%
% of Gross Profit
Research & Development $12.03M $7.374M
YoY Change 63.14% -1.11%
% of Gross Profit
Depreciation & Amortization $190.0K $90.00K
YoY Change 111.11% 12.5%
% of Gross Profit
Operating Expenses $15.81M $10.43M
YoY Change 51.5% 0.19%
Operating Profit -$13.65M -$9.971M
YoY Change 36.92% -1.91%
Interest Expense $502.0K $15.00K
YoY Change 3246.67% -71.15%
% of Operating Profit
Other Income/Expense, Net $502.0K $15.00K
YoY Change 3246.67% -96.27%
Pretax Income -$13.15M -$9.960M
YoY Change 32.03% 2.05%
Income Tax
% Of Pretax Income
Net Earnings -$13.20M -$9.956M
YoY Change 32.58% 8.58%
Net Earnings / Revenue -612.24% -2150.32%
Basic Earnings Per Share
Diluted Earnings Per Share -$744.2K -$692.6K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.4M $66.60M
YoY Change 55.26% 83.47%
Cash & Equivalents $71.13M $48.72M
Short-Term Investments $32.30M $17.90M
Other Short-Term Assets $5.400M $1.200M
YoY Change 350.0% 33.33%
Inventory
Prepaid Expenses
Receivables $900.0K
Other Receivables $3.000M
Total Short-Term Assets $112.7M $70.50M
YoY Change 59.84% 88.0%
LONG-TERM ASSETS
Property, Plant & Equipment $2.689M $1.000M
YoY Change 168.9% -23.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.449M $700.0K
YoY Change 249.86% 40.0%
Total Long-Term Assets $9.799M $2.100M
YoY Change 366.62% -19.23%
TOTAL ASSETS
Total Short-Term Assets $112.7M $70.50M
Total Long-Term Assets $9.799M $2.100M
Total Assets $122.5M $72.60M
YoY Change 68.72% 81.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.039M $700.0K
YoY Change 48.43% -50.0%
Accrued Expenses $7.000M $5.500M
YoY Change 27.27% 17.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.249M $6.600M
YoY Change 24.98% 3.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.600M $300.0K
YoY Change 1433.33% -25.0%
Total Long-Term Liabilities $4.600M $300.0K
YoY Change 1433.33% -25.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.249M $6.600M
Total Long-Term Liabilities $4.600M $300.0K
Total Liabilities $12.82M $7.300M
YoY Change 75.62% -12.05%
SHAREHOLDERS EQUITY
Retained Earnings -$156.7M
YoY Change
Common Stock $19.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $109.3M $65.30M
YoY Change
Total Liabilities & Shareholders Equity $122.5M $72.60M
YoY Change 68.73% 81.05%

Cashflow Statement

Concept 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$13.20M -$9.956M
YoY Change 32.58% 8.58%
Depreciation, Depletion And Amortization $190.0K $90.00K
YoY Change 111.11% 12.5%
Cash From Operating Activities -$12.07M -$8.640M
YoY Change 39.7% -2.7%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $24.93M $5.000M
YoY Change 398.6%
Cash From Investing Activities $24.85M $5.000M
YoY Change 397.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.960M -200.0K
YoY Change -4580.0% -82.76%
NET CHANGE
Cash From Operating Activities -12.07M -8.640M
Cash From Investing Activities 24.85M 5.000M
Cash From Financing Activities 8.960M -200.0K
Net Change In Cash 21.74M -3.840M
YoY Change -666.15% -61.75%
FREE CASH FLOW
Cash From Operating Activities -$12.07M -$8.640M
Capital Expenditures -$90.00K
Free Cash Flow -$11.98M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
001-38266
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
464590683
dei Entity Address Address Line1
EntityAddressAddressLine1
675 Massachusetts Avenue,
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Country
EntityAddressCountry
US
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
spro Grant Revenue
GrantRevenue
1616000
us-gaap Operating Expenses
OperatingExpenses
22403000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20787000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
81363000
CY2019Q2 us-gaap Lease Cost
LeaseCost
377000
CY2019Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67000
CY2019Q2 us-gaap Revenues
Revenues
2156000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-5072000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3220
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3220
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17205962
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17205962
spro Grant Revenue
GrantRevenue
6000000
CY2018Q2 spro Grant Revenue
GrantRevenue
463000
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
242-1600
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71133000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34080000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2720
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2720
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18650375
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18650375
CY2019Q2 spro Grant Revenue
GrantRevenue
2089000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3874000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7374000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3060000
us-gaap Revenues
Revenues
1616000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21552000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16299000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7670000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6104000
CY2019Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
32275000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
81363000
CY2019Q2 us-gaap Other Receivables
OtherReceivables
2073000
CY2018Q4 us-gaap Other Receivables
OtherReceivables
376000
CY2019Q2 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
921000
CY2018Q4 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
922000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6288000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7478000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
112690000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
124219000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2689000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2893000
CY2019Q2 spro Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
474000
CY2018Q4 spro Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
233000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4187000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2449000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1661000
CY2019Q2 us-gaap Assets
Assets
122489000
CY2018Q4 us-gaap Assets
Assets
129006000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1039000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3603000
CY2019Q2 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6416000
CY2018Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8263000
CY2019Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
223000
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
223000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
229000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
571000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8249000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12318000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
833000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4278000
CY2019Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
293000
CY2019Q2 us-gaap Liabilities
Liabilities
12820000
CY2018Q4 us-gaap Liabilities
Liabilities
13151000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
19000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
17000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
266013000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
254013000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156724000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138502000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
109314000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
115500000
CY2019Q2 us-gaap Minority Interest
MinorityInterest
355000
CY2018Q4 us-gaap Minority Interest
MinorityInterest
355000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109669000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
115855000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
10434000
us-gaap Operating Expenses
OperatingExpenses
29222000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9971000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19348000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1126000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
187000
us-gaap Profit Loss
ProfitLoss
-18222000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3782000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
15808000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13652000
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
502000
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
15000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1126000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
187000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
502000
CY2019Q2 us-gaap Profit Loss
ProfitLoss
-13150000
CY2018Q2 us-gaap Profit Loss
ProfitLoss
-9956000
us-gaap Profit Loss
ProfitLoss
-20600000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.43
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17667620
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14376529
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17445600
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14372876
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
28000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-6000
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5000
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
14000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
34000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-15000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13145000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9942000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18188000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20615000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
372000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
189000
us-gaap Share Based Compensation
ShareBasedCompensation
1866000
us-gaap Share Based Compensation
ShareBasedCompensation
1275000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
1000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-256000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
561000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
112000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1697000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-217000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1190000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-597000
spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
235000
spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
428000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
745000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2526000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2747000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2398000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
810000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-59000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-8000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22994000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20602000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32853000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
82537000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
22825000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
168000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
49516000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17825000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10251000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
79000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
247000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
359000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10531000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-196000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37053000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38623000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34080000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87338000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71133000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48715000
spro Offering Costs Included In Accounts Payable And Accrued Expenses
OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
79000
spro Offering Costs Included In Accounts Payable And Accrued Expenses
OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
246000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
59000
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1525000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
933000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
29000
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
113329000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
300000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8252000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
933000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
84957000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
614000
CY2018Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-29000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-10644000
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74898000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
661000
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65668000
us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim Financial Information</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated balance sheet at December&#160;31, 2018 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of June&#160;30, 2019, and for the three and six months ended June&#160;30, 2019 and 2018, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto for the year ended December&#160;31, 2018, included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2018,&#160;on file with SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company&#8217;s financial position as of June&#160;30, 2019, and results of operations for the three and six months ended June&#160;30, 2019 and 2018, and cash flows for the six months ended June&#160;30, 2019 and 2018 have been made. The results of operations for the three and six months ended June&#160;30, 2019 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2019.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for clinical trial costs and other research and development expenses, and the valuation of share-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</p>
spro Entity Incorporation Month And Year
EntityIncorporationMonthAndYear
2013-12
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
us-gaap Business Acquisition Date Of Acquisition Agreement1
BusinessAcquisitionDateOfAcquisitionAgreement1
2017-06-30
spro Business Combination Exchange Ratio
BusinessCombinationExchangeRatio
1
CY2019Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
4200000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
5400000
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
32269000
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
32275000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
81391000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000
us-gaap Lease Cost
LeaseCost
754000
us-gaap Operating Lease Payments
OperatingLeasePayments
632000
CY2019Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1346000
CY2019Q2 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentMember
CY2019Q2 spro Operating And Finance Lease Assets
OperatingAndFinanceLeaseAssets
5533000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4849000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
603000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
928000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
943000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1061000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1076000
CY2019Q2 spro Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
1092000
CY2019Q2 spro Lessee Operating Lease Liability Payments Due Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueThereafter
1108000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6811000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1962000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1361000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1054000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
995000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1107000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1123000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2246000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7886000
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2019Q2 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
3583000
CY2018Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4541000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1654000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2379000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
636000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
917000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
543000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
426000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3635225
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
376596
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
933000
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
661000
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5868481
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2236949
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5868481
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2236949

Files In Submission

Name View Source Status
0001564590-19-030746-index-headers.html Edgar Link pending
0001564590-19-030746-index.html Edgar Link pending
0001564590-19-030746.txt Edgar Link pending
0001564590-19-030746-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spro-10q_20190630.htm Edgar Link pending
spro-20190630.xml Edgar Link completed
spro-20190630.xsd Edgar Link pending
spro-20190630_cal.xml Edgar Link unprocessable
spro-20190630_def.xml Edgar Link unprocessable
spro-20190630_lab.xml Edgar Link unprocessable
spro-20190630_pre.xml Edgar Link unprocessable
spro-ex101_229.htm Edgar Link pending
spro-ex311_8.htm Edgar Link pending
spro-ex312_7.htm Edgar Link pending
spro-ex321_9.htm Edgar Link pending
spro-ex322_6.htm Edgar Link pending